Thomas Jefferson University

Mark Shahin

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address1025 Walnut St.
Philadelphia PA 19107
Phone215-481-6069
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Clements A, Enserro D, Strickland KC, Previs R, Matei D, Mutch D, Powell M, Klopp A, Miller DS, Small W, DiSilvestro P, Spirtos N, Cosgrove C, Sfakianos G, Liu JR, Vargas R, Shahin M, Corr B, Dessources K, Ueland F, Warshal D, Gillen J, Secord AA. Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258. Gynecol Oncol. 2025 Feb; 193:119-129. PMID: 39854806.
      Citations:    
    2. Ajmal N, Nicolais O, Shahin MS, Ma L. Pilomatrix-like High-grade Endometrioid Carcinoma of the Uterine Corpus With Excellent Response to Immune Checkpoint Inhibitor Therapy. Int J Gynecol Pathol. 2024 Dec 27. PMID: 39726104.
      Citations:    
    3. Matei DE, Enserro DM, Randall ME, Mutch D, Small W, DiSilvestro PA, Spirtos NM, O'Malley DM, Cantuaria GH, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland FR, Warshal D, Bonebrake A, Tewari KS, Tan A, Powell MA, Walker JL, Santin AD, Kim JH, Miller DS. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. J Clin Oncol. 2024 Dec 19; JCO2401121. PMID: 39700442.
      Citations:    
    4. Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gynecol Oncol. 2024 Nov 11; 192:40-49. PMID: 39531903.
      Citations:    
    5. Kuchimanchi M, J?rgensen TL, Hanze E, Andr? T, Jain A, Berton D, Alsk?r O, Zub O, Oaknin A, Shahin MS, Koliadi A, Pothuri B, Krivak T, Pishchyk M, Segev Y, Backes FJ, Gennigens C, Bouberhan S, Zajic S, Melhem M, Buscema J. Population pharmacokinetics and exposure-response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY. Br J Clin Pharmacol. 2024 Nov 08. PMID: 39520048.
      Citations:    
    6. Monk BJ, Barretina-Ginesta MP, Pothuri B, Vergote I, Graybill W, Mirza MR, McCormick CC, Lorusso D, Moore RG, Freyer G, O'Cearbhaill RE, Heitz F, O'Malley DM, Redondo A, Shahin MS, Vulsteke C, Bradley WH, Haslund CA, Chase DM, Pisano C, Holman LL, P?rez MJR, DiSilvestro P, Gaba L, Herzog TJ, Bruchim I, Compton N, Shtessel L, Malinowska IA, Gonz?lez-Mart?n A. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann Oncol. 2024 Nov; 35(11):981-992. PMID: 39284381.
      Citations:    
    7. Mirza MR, Chase DM, Slomovitz BM, Christensen RD, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. A Plain Language Summary of "Dostarlimab for primary advanced or recurrent endometrial cancer". Future Oncol. 2024 Jul 11; 1-18. PMID: 38990090.
      Citations:    
    8. Nicolais O, Cummings M, Buchanan TR, Moukarzel L, Cardillo N, Burton E, Edelson MI, Shahin MS. Vaginal lacerations during laparoscopic hysterectomy for endometrial cancer and local recurrence risk. Gynecol Oncol Rep. 2024 Aug; 54:101433. PMID: 39006218.
      Citations:    
    9. Powell MA, Bj?rge L, Willmott L, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Gropp-Meier M, Stuckey A, Boere I, Gold MA, Segev Y, Gill SE, Gennigens C, Sebastianelli A, Shahin MS, Pothuri B, Monk BJ, Buscema J, Coleman RL, Slomovitz BM, Ring KL, Herzog TJ, Balas MM, Grimshaw M, Stevens S, Lai DW, McCourt C, Mirza MR. Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug; 35(8):728-738. PMID: 38866180.
      Citations:    
    10. Fader AN, Ko EM, Pollock BD, Blank SV, Cohn DE, Huh W, Shahin MS, Dowdy SC. An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care? Gynecol Oncol. 2024 Mar; 182:188-191. PMID: 38493022.
      Citations:    
    11. Chan JK, Tian C, Kesterson JP, Lin KY, Darcy K, Richardson MT, Kapp DS, Monk BJ, McNally L, Landrum L, Copeland L, Walker JL, Wenham RM, Phippen N, Spirtos NM, Tewari K, Shahin M, Berry L, Bell JG. Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study. Gynecol Oncol. 2023 Dec 21; 181:54-59. PMID: 38134754.
      Citations:    
    12. O'Cearbhaill RE, Miller A, Soslow RA, Lankes HA, DeLair D, Segura S, Chavan S, Zamarin D, DeBernardo R, Moore K, Moroney J, Shahin M, Thaker PH, Wahner-Hendrickson AE, Aghajanian C. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283. Gynecol Oncol. 2023 Jul 05; 176:16-24. PMID: 37418832.
      Citations:    
    13. Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Nov?k Z, Black D, Gilbert L, Sharma S, Valabrega G, Landrum LM, Hanker LC, Stuckey A, Boere I, Gold MA, Auranen A, Pothuri B, Cibula D, McCourt C, Raspagliesi F, Shahin MS, Gill SE, Monk BJ, Buscema J, Herzog TJ, Copeland LJ, Tian M, He Z, Stevens S, Zografos E, Coleman RL, Powell MA. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023 Mar 27. PMID: 36972026.
      Citations:    
    14. Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath Iii CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023 Mar 27. PMID: 36972022.
      Citations:    
    15. Cummings M, Edmonds P, Shahin MS, Sorosky JI. Juvenile granulosa cell tumor in an adult woman during pregnancy: A case report and review of the literature. Gynecol Oncol Rep. 2023 Apr; 46:101164. PMID: 36992983.
      Citations:    
    16. Blank SV, Huh WK, Bell M, Dilley S, Hardesty M, Hoskins ER, Lachance J, Musa F, Prendergast E, Rimel BJ, Shahin M, Valea F. Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report. Gynecol Oncol. 2023 Feb 22; 171:76-82. PMID: 36827841.
      Citations:    
    17. Leitao MM, Zhou QC, Brandt B, Iasonos A, Sioulas V, Lavigne Mager K, Shahin M, Bruce S, Black DR, Kay CG, Gandhi M, Qayyum M, Scalici J, Jones NL, Paladugu R, Brown J, Naumann RW, Levine MD, Mendivil A, Lim PC, Kang E, Cantrell LA, Sullivan MW, Martino MA, Kratz MK, Kolev V, Tomita S, Leath CA, Boitano TKL, Doo DW, Feltmate C, Sugrue R, Olawaiye AB, Goldfeld E, Ferguson SE, Suhner J, Abu-Rustum NR. The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes. Gynecol Oncol. 2022 09; 166(3):417-424. PMID: 35879128.
      Citations:    
    18. O'Cearbhaill RE, P?rez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, D?rum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, Gonz?lez-Mart?n A. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. Gynecol Oncol. 2022 07; 166(1):36-43. PMID: 35550709.
      Citations:    
    19. Cummings M, Nicolais O, Shahin M. Surgery in Advanced Ovary Cancer: Primary versus Interval Cytoreduction. Diagnostics (Basel). 2022 Apr 14; 12(4). PMID: 35454036.
      Citations:    
    20. Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253. PMID: 34906376.
      Citations:    
    21. Shahin MS. Fighting for a Fair Day's Wage. Obstet Gynecol. 2021 08 01; 138(2):180-181. PMID: 34237763.
      Citations:    
    22. Joshi TV, Bruce SF, Grim R, Buchanan T, Chatterjee-Paer S, Burton ER, Sorosky JI, Shahin MS, Edelson MI. Implementation of an enhanced recovery protocol in gynecologic oncology. Gynecol Oncol Rep. 2021 May; 36:100771. PMID: 34036136.
      Citations:    
    23. Holtz DO, Shahin MS. Changes to outpatient evaluation and management coding: 2021 will be a better year. Gynecol Oncol. 2021 06; 161(3):871-875. PMID: 33744006.
      Citations:    
    24. Gonz?lez-Mart?n A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-P?rez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2391-2402. PMID: 31562799.
      Citations:    
    25. Bruce SF, Joshi TV, Chervoneva I, Yi M, Chatterjee-Paer S, Burton ER, Edelson MI, Sorosky JI, Shahin MS. Disparities Among Cervical Cancer Patients Receiving Brachytherapy. Obstet Gynecol. 2019 Sep; 134(3):559-569. PMID: 31403593.
      Citations:    
    26. Bovi JA, Pugh SL, Sabsevitz D, Robinson CG, Paulson E, Mehta MP, Gondi V, Kundapur V, Shahin MS, Chao ST, Machtay M, DeNittis AS, Laack NN, Greenspoon JN, Moore KN, Huang J, Dominello MM, Kachnic LA. Pretreatment Volume of MRI-Determined White Matter Injury Predicts Neurocognitive Decline After Hippocampal Avoidant Whole-Brain Radiation Therapy for Brain Metastases: Secondary Analysis of NRG Oncology Radiation Therapy Oncology Group 0933. Adv Radiat Oncol. 2019 Oct-Dec; 4(4):579-586. PMID: 31673651.
      Citations:    
    27. Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecol Oncol. 2018 08; 150(2):247-252. PMID: 29921512.
      Citations:    
    28. Bruce SF, Carr DN, Burton ER, Sorosky JI, Shahin MS, Naglak MC, Edelson MI. Implementation of an abdominal closure bundle to reduce surgical site infection in patients on a gynecologic oncology service undergoing exploratory laparotomy. Gynecol Oncol. 2018 06; 149(3):560-564. PMID: 29548786.
      Citations:    
    29. Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 01; 36(4):414-424. PMID: 29236593.
      Citations:    
    30. Jafri SIM, Ali N, Farhat S, Malik F, Shahin M. The tell-tale heart: A case of recurrent vulvar carcinoma with cardiac metastasis and review of literature. Gynecol Oncol Rep. 2017 Aug; 21:20-23. PMID: 28664179.
      Citations:    
    31. Uppal S, Shahin MS, Rathbun JA, Goff BA. Since surgery isn't getting any easier, why is reimbursement going down? An update from the SGO taskforce on coding and reimbursement. Gynecol Oncol. 2017 Feb; 144(2):235-237. PMID: 27287507.
      Citations:    
    32. Sorosky JI, Burton ER, Edelson MI, Shahin MS. American College of Surgeons Clinical Congress 2016. Gynecol Oncol. 2017 03; 144(3):456-458. PMID: 27939983.
      Citations:    
    33. Miles M, Ward C, Pezzi CM, Kelley CA, Pezzi T, Seelaus J, Shahin M, McGrath G. Primary Pelvic Papillary Thyroid Carcinoma with Metastases to Peritoneal Surfaces. Am Surg. 2016 Nov 01; 82(11):1148-1150. PMID: 28206948.
      Citations:    
    34. Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, Backes F, Tenney ME, Mathews CA, Hoffman JS, Aghajanian C, Hensley ML. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecol Oncol. 2017 Jan; 144(1):96-100. PMID: 28094040.
      Citations:    
    35. Goff BA, Shahin MS, Powell MA, Dowdy SC. SGO Health Policy and Socioeconomic Committee: Current and Future Efforts of the Coding and Reimbursement Taskforce and the Policy, Quality and Outcomes Taskforce. Gynecol Oncol. 2016 11; 143(2):229-230. PMID: 27692694.
      Citations:    
    36. Dalton HJ, Fiorica JV, Edwards RP, Benjamin I, Rocconi RP, Recio FO, Lovecchio JL, Burrell MO, Shahin MS, Grendys EC, Wang D, Wang T, Monk BJ. In vitro chemoresponse in metachronous pairs of ovarian cancers. Anticancer Res. 2014 Dec; 34(12):7191-6. PMID: 25503148.
      Citations:    
    37. Martin LP, Sill M, Shahin MS, Powell M, Disilvestro P, Landrum LM, Gaillard SL, Goodheart MJ, Hoffman J, Schilder RJ. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2014 Mar; 132(3):526-30. PMID: 24361733.
      Citations:    
    38. Alvarez RD, Gray HJ, Timmins PF, Gibb RK, Edelson M, Fowler JM, Havrilesky LJ, McCauley DL, Nash JD, Rahaman J, Rash JK, Rodabaugh KJ, Powell MA, Bristow RE, Brown JV, Tewari D, Cliby WA, Anastasia P, Robinson WR, Shahin MS, Cantrell LA, Cloven NG, Gold MA, Hope JM, Muntz HG, Sorosky JI, Elkas JC, Frumovitz MM, Jewell E, Spillman MA, Naumann RW. We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policies. Gynecol Oncol. 2013 Apr; 129(1):3-4. PMID: 23638463.
      Citations:    
    39. Schilder RJ, Brady WE, Lankes HA, Fiorica JV, Shahin MS, Zhou XC, Mannel RS, Pathak HB, Hu W, Alpaugh RK, Sood AK, Godwin AK. Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4. PMID: 22710075.
      Citations:    
    40. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, Hoffman JS, Shahin MS. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul; 122(1):111-5. PMID: 21497382.
      Citations:    
    41. Herzog TJ, Sill MW, Walker JL, O'Malley D, Shahin M, DeGeest K, Weiner SA, Mutch D, DeBernardo RL, Lentz SS. A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group Study (GOG 146Q). Gynecol Oncol. 2011 Mar; 120(3):454-8. PMID: 21168198.
      Citations:    
    42. Schilder RJ, Blessing JA, Shahin MS, Miller DS, Tewari KS, Muller CY, Warshal DP, McMeekin S, Rotmensch J. A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial. Int J Gynecol Cancer. 2010 Oct; 20(7):1137-41. PMID: 21495215.
      Citations:    
    43. Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, Warshal DP, Abulafia O, Richards WE, Van Le L. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2010 Aug 01; 118(2):139-44. PMID: 20452658.
      Citations:    
    44. Rocereto TF, Brady WE, Shahin MS, Hoffman JS, Small L, Rotmensch J, Mannel RS. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010 Mar; 116(3):332-4. PMID: 19922989.
      Citations:    
    45. Bruner DW, Nolte SA, Shahin MS, Huang HQ, Sobel E, Gallup D, Cella D. Measurement of vaginal length: Reliability of the vaginal sound--a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1749-55. PMID: 17009966.
      Citations:    
    46. Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 1):6080-5. PMID: 15447993.
      Citations:    
    47. Sood AK, Nygaard I, Shahin MS, Sorosky JI, Lutgendorf SK, Rao SS. Anorectal dysfunction after surgical treatment for cervical cancer. J Am Coll Surg. 2002 Oct; 195(4):513-9. PMID: 12375757.
      Citations:    
    48. Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002 Jul; 9(7):553-66. PMID: 12082455.
      Citations:    
    49. Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500. Cancer Gene Ther. 2002 Jul; 9(7):567-72. PMID: 12082456.
      Citations:    
    50. Hanjani P, Nolte S, Shahin MS. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer. Gynecol Oncol. 2002 May; 85(2):278-84. PMID: 11972388.
      Citations:    
    51. Buller RE, Shahin MS, Geisler JP, Zogg M, De Young BR, Davis CS. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res. 2002 May; 8(5):1196-202. PMID: 12006538.
      Citations:    
    52. Jondle DM, Shahin MS, Sorosky J, Benda JA. Ovarian mixed germ cell tumor with predominance of polyembryoma: a case report with literature review. Int J Gynecol Pathol. 2002 Jan; 21(1):78-81. PMID: 11781529.
      Citations:    
    53. Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol. 2001 Dec; 83(3):599-600. PMID: 11733979.
      Citations:    
    54. Buller RE, Lallas TA, Shahin MS, Sood AK, Hatterman-Zogg M, Anderson B, Sorosky JI, Kirby PA. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. Clin Cancer Res. 2001 Apr; 7(4):831-8. PMID: 11309330.
      Citations:    
    55. Buller RE, Shahin MS, Holmes RW, Hatterman M, Kirby PA, Sood AK. p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. Am J Obstet Gynecol. 2001 Apr; 184(5):891-902; discussion 902-3. PMID: 11303196.
      Citations:    
    56. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000 Nov 01; 89(9):2006-17. PMID: 11064359.
      Citations:    
    57. Lallas TA, McClain SK, Shahin MS, Buller RE. The glutathione S-transferase M1 genotype in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2000 Jun; 9(6):587-90. PMID: 10868693.
      Citations:    
    58. Shahin MS, Puscheck E. Reproductive sequelae of cancer treatment. Obstet Gynecol Clin North Am. 1998 Jun; 25(2):423-33. PMID: 9629582.
      Citations:    
    Shahin's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (196)
    Explore
    _
    Co-Authors (24)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _